SCHEMBL9934722

SCHEMBL9934722

CC1CN(C(=O)OC(C)(C)C)CCN1Cc1nc2ccccc2o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 1/20 0.45
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
GPR119 Q8TDV5 6/20 0.41
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
ABCB1 P08183 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963107 1.00 TBK1 (0.45) TBK1SMARCA2SMARCA4PBRM1GPR119
SCHEMBL9934812 0.83 KMT2A (0.46) GAAKMT2ANPC1RAB9ALMNA
SCHEMBL9963101 0.83 CHRM2 (0.50) TBK1GPR119GAAKMT2ACKS1B
SCHEMBL14198702 0.78 GPR119 (0.50) SMARCA2SMARCA4PBRM1GPR119CHRM1
SCHEMBL12340707 0.78 GPR119 (0.50) SMARCA2SMARCA4PBRM1GPR119CHRM1
SCHEMBL15055262 0.78 GPR119 (0.50) SMARCA2SMARCA4PBRM1GPR119CHRM1
SCHEMBL9933038 0.78 GPR119 (0.48) TBK1SMARCA2SMARCA4PBRM1GPR119
SCHEMBL9966006 0.77 NPC1 (0.45) KMT2ANPC1RAB9ALMNAHTT
SCHEMBL31155355 0.77 TBK1 (0.43) TBK1SMARCA2SMARCA4PBRM1GPR119
SCHEMBL30918491 0.76 GPR119 (0.48) TBK1SMARCA2SMARCA4PBRM1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 TBK1 1348/4885SMARCA2 4188/4885SMARCA4 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.